Status re Novo Nordisk's holding of its own shares (30 September
2007)
In continuation of the company's announcement dated 31 January 2007
concerning a planned share repurchase programme, and pursuant to
Section 204.25 of the New York Stock Exchange Listed Company Manual,
this is to report that Novo Nordisk A/S (NYSE: NVO) and its
wholly-owned affiliates on 30 September 2007 owned 9,925,484 of its
own B shares of DKK 2, corresponding to a total nominal value of DKK
19,850,968 or 3.07% of the total share capital. Hereof the
wholly-owned affiliates owned 99,000 B shares of DKK 2, corresponding
to a total nominal value of DKK 198,000 or 0.03% of the total share
capital.
In the third quarter of 2007 4,518,750 B shares were repurchased by
Novo Nordisk A/S, and 107,880 B shares were disposed of to employees
who exercised options granted by Novo Nordisk.
Novo Nordisk is a healthcare company and a world leader in diabetes
care. The company has the broadest diabetes product portfolio in the
industry, including the most advanced products within the area of
insulin delivery systems. In addition, Novo Nordisk has a leading
position within areas such as haemostasis management, growth hormone
therapy and hormone replacement therapy. Novo Nordisk manufactures
and markets pharmaceutical products and services that make a
significant difference to patients, the medical profession and
society. With headquarters in Denmark, Novo Nordisk employs
approximately 23,600 full-time employees in 79 countries, and markets
its products in 179 countries. Novo Nordisk's B shares are listed on
the stock exchanges in Copenhagen and London. Its ADRs are listed on
the New York Stock Exchange under the symbol 'NVO'. For more
information, visit novonordisk.com.
For further information please contact:
Media: Investors:
Outside North America: Outside North America:
Elin K Hansen Mads Veggerby Lausten
Tel: (+45) 4442 3450 Tel: (+45) 4443 7919
ekh@novonordisk.com mlau@novonordisk.com
Hans Rommer
Tel: (+45) 4442 4765
hrmm@novonordisik.com
In North America: In North America:
Sean Clements Christian Qvist Frandsen
Tel: (+1) 609 514 8316 Tel: (+1) 609 919 7937
secl@novonordisk.com cqfr@novonordisk.com
Stock Exchange Announcement no 26 / 2007